CLOs on the Move

Argentis Pharmaceuticals

www.argentisrx.com

 
arGentis™ Pharmaceuticals, LLC is a private TN based pharmaceutical company with a mid-stage Orphan Drug treatment (ARG201) for late stage diffuse systemic scleroderma (dcSSc). The company is seeking capital or a partner to complete a Pivotal Clinical Trial which will enable obtaining marketing approval in the EU. The Company has a genotype marker (ROT1) that predicts patient response to treatment by oral tolerance for treatments like ARG201 for dcSSc. Furthermore, arGentis™ has a treatment for Rheumatoid arthritis (ARG301) that is in a Phase I Clinical Trial in the US.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.argentisrx.com
  • 1016 W. Poplar Ave. Suite 106-238
    Collierville, TN USA 38017
  • Phone: 901.881.8665

Executives

Name Title Contact Details

Similar Companies

WholesomeCo Cannabis

WholesomeCo is a pharmacy in West Bountiful, UT delivering to many areas across the state. Find the best flower, edibles, & more for your cannabis-based treatment.

Marquez Process Service

Marquez Process Service is a Bellingham, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Minakem

Minakem is a Hackensack, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Vical

Vical Incorporated is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

VistaGen

VistaGen (Nasdaq: VTGN) is a late clinical-stage, CNS-focused biopharmaceutical company striving to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. The Company is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those that are currently available. VistaGen`s clinical-stage candidates are targeting multiple forms of anxiety and depression. They belong to a new class of drugs known as pherines, which are odorless, tasteless, neuroactive steroids that bind to distinct receptors on chemosensory neurons in the nasal passages and can impact the limbic amygdala without systemic uptake or direct activity on CNS neurons in the brain. VistaGen`s lead candidate, PH94B, is a nasally administered spray currently in multiple Phase 3 trials in the U.S., with results anticipated in 2022. Should ongoing Phase 3 studies be successful, PH94B has the potential to be the first FDA-approved, fast-acting, acute treatment of anxiety for adults with social anxiety disorder. With an experienced leadership team, VistaGen is passionate about transforming mental health care and redefining what is possible in the treatment of anxiety and depression.